On Jun 29, 2018 Raymond James Analyzed Intercept Pharmaceuticals (NASDAQ:ICPT) with $122 Target.

June 29, 2018 - By Loretta Love

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Corporate Logo

During 2018 Q1 the big money sentiment decreased to 1.15. That’s change of 0.16, from 2017Q4’s 1.31. 24 investors sold all, 35 reduced holdings as Intercept Pharmaceuticals, Inc. ratio worsened. 48 grew stakes while 20 funds bought stakes. Funds hold 18.85 million shares thus 4.89% more from 2017Q4’s 17.97 million shares.

Goldman Sachs Gp holds 141,487 shs. Trexquant Inv Limited Partnership has 0.16% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 37,238 shs. Vermont-based Birchview Capital Lp has invested 0.17% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). The Maryland-based Profund Advsr Limited Com has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Susquehanna International Llp stated it has 142,218 shs. Barclays Pcl reported 86,309 shs. Group Inc One Trading L P reported 24,444 shs stake. Ellington Mgmt Grp Lc holds 0.02% of its capital in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 5,100 shs. Principal Finance Group Inc has 4,511 shs for 0% of their capital. Point72 Asia (Hong Kong) holds 0.01% or 440 shs. Credit Suisse Ag reported 0.01% stake. Blackrock owns 1.28M shs. Fisher Asset Mgmt Ltd Liability Corporation has 70,252 shs. Northwestern Mutual Wealth Management has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 87 shs. Pictet Asset Mngmt Ltd accumulated 51,600 shs.

What Price Target Has Raymond James Given Intercept Pharmaceuticals (NASDAQ:ICPT)

Today a research note was issued to clients, in which Raymond James analyst initiated coverage of Intercept Pharmaceuticals (NASDAQ:ICPT) with “Strong Buy” rating. The Equity analysts give $122 target which means upside potential of 45.01 % on ICPT’s shares.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

A total of 7 analysts rate Intercept Pharma (NASDAQ:ICPT) as follows: 5 “Buy”, 1 “Hold” and 1 “Sell”. Тherefore 71% are bullish. (NASDAQ:ICPT) has 10 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Thursday, February 1 the stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Buy” rating given by Wedbush. On Monday, January 22 Credit Suisse maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) with “Buy” rating. On Tuesday, February 13 the firm has “Hold” rating by Wells Fargo given. The company rating was maintained by Wedbush on Tuesday, April 17. On Monday, February 12 Wedbush maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating. Wedbush has “Buy” rating and $253.0 target. On Wednesday, February 7 the stock has “Sell” rating by Goldman Sachs. On Thursday, February 15 the rating was maintained by BMO Capital Markets with “Outperform”. On Thursday, January 25 the stock has “Buy” rating by Wedbush.

ICPT hit $84.13 during the last trading session after $4.23 change.Currently Intercept Pharmaceuticals, Inc. is downtrending after 38.34% change in last June 29, 2017. ICPT has 264,180 shares volume. ICPT underperformed the S&P500 by 50.91%.

Investors expect Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)’s quarterly earnings on July, 30., according to Zacks. This year’s EPS analyst estimate is expected to be $-2.94. That is 15.03 % up compareed to $-3.46 EPS for last year. Wall Street now predicts -8.70 % EPS growth despite Intercept Pharmaceuticals, Inc. last quarter’s EPS of $-3.22.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada.The firm is worth $2.49 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).Last it reported negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia.

For more Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news posted recently go to: Fool.com, Seekingalpha.com, Seekingalpha.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It” posted on June 26, 2018, “Lipotoxicity And Liver Diseases-NASH And PBC: Is Enanta A Player Or Spectator?” on June 01, 2018, “Intercept Pharmaceuticals: Buyout Speculation Stokes Shares” with a publish date: June 12, 2018, “Benzinga’s Top Upgrades, Downgrades For June 28, 2018” and the last “Intercept’s Obeticholic Acid Therapy And NASH: The Scientific Truth Is That Every Cloud Has A Silver Lining” with publication date: June 13, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: